Alnylam Pharmaceuticals, Inc. (ALNY) SVP Laurie Keating Sells 6,249 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) SVP Laurie Keating sold 6,249 shares of the company’s stock in a transaction dated Wednesday, December 20th. The shares were sold at an average price of $121.20, for a total transaction of $757,378.80. Following the transaction, the senior vice president now owns 17,749 shares in the company, valued at $2,151,178.80. The sale was disclosed in a filing with the SEC, which is available at this hyperlink.

Laurie Keating also recently made the following trade(s):

  • On Friday, December 1st, Laurie Keating sold 30,000 shares of Alnylam Pharmaceuticals stock. The shares were sold at an average price of $135.89, for a total transaction of $4,076,700.00.

Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) traded up $1.13 during mid-day trading on Friday, reaching $123.96. 1,029,400 shares of the company’s stock were exchanged, compared to its average volume of 1,145,938. The company has a debt-to-equity ratio of 0.14, a current ratio of 9.83 and a quick ratio of 9.83. The company has a market cap of $12,080.00, a P/E ratio of -23.61 and a beta of 2.97. Alnylam Pharmaceuticals, Inc. has a twelve month low of $35.98 and a twelve month high of $147.63.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its earnings results on Tuesday, November 7th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Zacks’ consensus estimate of ($1.23) by ($0.11). The company had revenue of $17.10 million during the quarter, compared to the consensus estimate of $28.15 million. Alnylam Pharmaceuticals had a negative return on equity of 46.94% and a negative net margin of 664.70%. Alnylam Pharmaceuticals’s revenue was up 24.8% on a year-over-year basis. During the same quarter in the prior year, the company earned ($1.21) earnings per share. analysts expect that Alnylam Pharmaceuticals, Inc. will post -5.21 earnings per share for the current fiscal year.

Several institutional investors and hedge funds have recently made changes to their positions in ALNY. Dimensional Fund Advisors LP lifted its position in shares of Alnylam Pharmaceuticals by 1.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 112,778 shares of the biopharmaceutical company’s stock worth $5,780,000 after purchasing an additional 1,428 shares during the period. Bank of Montreal Can lifted its position in shares of Alnylam Pharmaceuticals by 4.7% in the 2nd quarter. Bank of Montreal Can now owns 9,974 shares of the biopharmaceutical company’s stock worth $796,000 after purchasing an additional 446 shares during the period. Schwab Charles Investment Management Inc. lifted its position in shares of Alnylam Pharmaceuticals by 33.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 243,415 shares of the biopharmaceutical company’s stock worth $19,415,000 after purchasing an additional 60,906 shares during the period. State of Wisconsin Investment Board lifted its position in shares of Alnylam Pharmaceuticals by 0.7% in the 2nd quarter. State of Wisconsin Investment Board now owns 15,012 shares of the biopharmaceutical company’s stock worth $1,197,000 after purchasing an additional 100 shares during the period. Finally, Bank of New York Mellon Corp lifted its position in shares of Alnylam Pharmaceuticals by 9.2% in the 2nd quarter. Bank of New York Mellon Corp now owns 333,942 shares of the biopharmaceutical company’s stock worth $26,634,000 after purchasing an additional 28,260 shares during the period. 88.39% of the stock is owned by hedge funds and other institutional investors.

Several brokerages recently commented on ALNY. JMP Securities upped their price target on shares of Alnylam Pharmaceuticals from $101.00 to $128.00 and gave the company an “outperform” rating in a report on Wednesday, September 20th. Barclays upped their price target on shares of Alnylam Pharmaceuticals from $127.00 to $158.00 and gave the company an “overweight” rating in a report on Wednesday, November 8th. Piper Jaffray Companies reiterated an “overweight” rating and set a $110.00 price target (down from $126.00) on shares of Alnylam Pharmaceuticals in a report on Thursday, September 7th. FBR & Co began coverage on shares of Alnylam Pharmaceuticals in a report on Monday, October 30th. They set a “buy” rating and a $150.00 price target on the stock. Finally, Cowen reiterated an “outperform” rating and set a $151.00 price target (up from $117.00) on shares of Alnylam Pharmaceuticals in a report on Friday, November 3rd. Three research analysts have rated the stock with a sell rating, seven have assigned a hold rating, fifteen have assigned a buy rating and one has issued a strong buy rating to the company. The stock has a consensus rating of “Buy” and an average target price of $121.85.

WARNING: This article was originally reported by Community Financial News and is the property of of Community Financial News. If you are viewing this article on another site, it was copied illegally and republished in violation of United States & international copyright and trademark laws. The legal version of this article can be read at https://www.com-unik.info/2017/12/22/alnylam-pharmaceuticals-inc-alny-svp-laurie-keating-sells-6249-shares.html.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).

Insider Buying and Selling by Quarter for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Receive News & Ratings for Alnylam Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit